DMK Pharmaceuticals Corporation (NASDAQ:DMK) has announced a series of management changes, including the appointment of Seth Cohen as Chief Financial Officer and John Dorbin as General Counsel Corporate Secretary. The changes are aimed at optimizing the company's leadership structure, increasing sales of existing products, and advancing its clinical pipeline. Both Cohen and Dorbin bring extensive experience in their respective fields. Cohen has over thirty years of experience in business and finance, while Dorbin has over two decades of experience representing publicly traded companies and serving as an independent business consultant.